A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.
Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA.
Stover EH, et al. Among authors: myers ap.
Gynecol Oncol Rep. 2022 Mar 31;40:100974. doi: 10.1016/j.gore.2022.100974. eCollection 2022 Apr.
Gynecol Oncol Rep. 2022.
PMID: 35434236
Free PMC article.